Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Two House subcommittees are holding hearings on the baby formula crisis. One will focus on the Food and Drug Administration and the formula makers. The other will look at the effects of the shortage.
-
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them.
-
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.
-
Former scientific head of Operation Warp Speed Moncef Slaoui explains why he is confident in existing vaccines' protection against omicron and how soon a variant-specific booster could be developed.
-
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why.
-
If all goes to plan, Americans who got Pfizer or Moderna shots can get a third dose eight months after their last jab. Here's why health officials think you'll need one.
-
House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine.
-
President Biden threw his support behind a World Trade Organization proposal that would waive intellectual property protections for COVID-19 vaccines — allowing countries to make their own vaccines.
-
A dip of 86% in doses to be distributed to states follows a surge that occurred after one of J&J's third party manufacturers was finally able to release a stockpile.
-
The COVID-19 vaccine by Johnson and Johnson has hit a snag. One the facilities making a key ingredient didn't pass quality inspection — possibly impacting 15 million doses.